Omeros announces preliminary results from phase 1 clinical trial of oms906

Seattle--(business wire)--omeros corporation (nasdaq: omer), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, immunologic diseases (e.g., complement-mediated diseases and cancers) and central nervous system disorders, today announced preliminary results from the phase 1 clinical trial of its masp-3 inhibitor oms906. the ongoing trial
OMER Ratings Summary
OMER Quant Ranking